Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 7/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465329 | 1.00 | KCNA5 (0.50) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL30682711 | 1.00 | KCNA5 (0.50) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL30360441 | 1.00 | KCNA5 (0.50) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| SCHEMBL1579392 | 1.00 | KCNA5 (0.50) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6776168 | 0.98 | KCNA5 (0.49) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6081585 | 0.98 | KCNA5 (0.49) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL7426262 | 0.98 | KCNA5 (0.49) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| Hydrochloric Acid SCHEMBL7929348 | 0.98 | KCNA5 (0.49) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6771556 | 0.98 | KCNA5 (0.49) | KCNA5KCNH2TSHRKCNE1CYP2D6 | |
| Hypochlorous Acid SCHEMBL20677392 | 0.94 | KCNA5 (0.46) | KCNA5KCNH2TSHRKCNE1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115838509-B | POE elastomer composite material modified based on dual-dynamic cross-linked network and preparation method thereof | 广东工业大学 | 2024-07-19 | — | — | CN | claimed |
| CN-115838509-A | POE elastomer composite material based on double dynamic cross-linked network modification and preparation method thereof | 广东工业大学 | 2023-03-24 | — | — | CN | claimed |
| EP-2391606-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | claimed |
| WO-2010074647-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | claimed |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | claimed |
| EP-1915362-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | claimed |
| WO-2007018465-A1 | AMIDE ALKYL PYRIDIYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | claimed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | claimed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | claimed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| CN-115838509-B | POE elastomer composite material modified based on dual-dynamic cross-linked network and preparation method thereof | 广东工业大学 | 2024-07-19 | — | — | CN | disclosed |
| CN-114072207-B | Bicyclic compounds | 维瓦斯治疗公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| CN-114539137-B | Chiral alpha-heteroaryl amine and preparation method thereof | 河北工业大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-115894447-A | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-5238588-A | Oil additive which is a graft polymer consisting of an alpha-olefin, acylating and aminoheteroaromatic compound | TEXACO INC. (US) | 1993-08-24 | — | — | US | disclosed |
| US-5156758-A | Addition terpolymer of ethylene, alpha-olefin and unsaturated acid or ester, modified with amine copounds | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| US-5147571-A | Mixing ethylene polymer with methacrylamido glycolate methyl ether, reacting product with amine | TEXACO INC. (US) | 1992-09-15 | — | — | US | disclosed |
| EP-0417904-A1 | Method for producing dispersant, VI improver, additive for lubricating oil | TEXACO DEVELOPMENT CORPORATION (US) | 1991-03-20 | — | — | EP | disclosed |
| EP-0321624-A1 | Polymeric amides for multifunctional VI improvers | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | KCNA5 3623/4885KCNH2 3454/4885TSHR 1883/4885 |
| US-20080200504-A1 | non-peptide NK-3 receptor ligands; anxiety, depression, schizophrenia, obesity; 2-Phenyl-quinoline-4-carboxylic acid (1-pyridin-4-yl-propyl) amide; reacting the 2-phenyl-quinolinyl-4-carbonyl chloride with a pyridylalkylamine to form the amide | NPY4R, PROKR1, NPSR1 | KCNA5 76/4885KCNH2 47/4885TSHR 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.